Suicidal behaviour caused by antidepressants 'cannot be ruled out'

Antidepressant Safety Debate May Include Adult Patients

Antidepressant Safety Debate May Include Adult Patients

The yearlong debate over whether antidepressant drugs increase the risk of suicide in some children may soon widen to include adults, as English and Canadian scientists are reporting findings from three new analyses of suicide risk in people over age 18 who have taken the medications.

The new findings are mixed, and apparently contradictory, and likely to encourage both patient advocates who believe that antidepressants like Prozac have hidden dangers, and manufacturers who insist that the medications are safe, experts said.

One of the reports, an analysis of data on antidepressants from previous studies, found that adults taking the drugs were twice as likely to attempt suicide as those receiving a dummy pill or other treatments, but no more likely to complete the act.

The two other reports found no significant link between the medications and suicide. Suicide attempts occurred in less than 0.5 percent of the more than 200,000 people included in the three studies.

All three papers appeared yesterday in the online version of The British Medical Journal.

"There has been a phenomenal amount of pressure to study this issue in adults," in part because of the debate over the risk in children, said Dr. John Geddes, a professor of epidemiological psychiatry at Oxford University and the co-author of an accompanying editorial in the journal. Dr. Geddes was not involved in the studies and has received research money from drug makers.

"We know a certain amount of negative evidence on these drugs has been suppressed, and the more information we have on them in the public domain, the better to guide clinical practice," he said.

In the early 1990's, a panel of experts convened by the Food and Drug Administration concluded that there was not enough evidence to link drugs like Prozac and Zoloft to increased suicide risk and most psychiatrists say that the drugs are more likely to prevent suicide.

But regulators in the United States and Britain recently issued warnings that the drugs, known as selective serotonin reuptake inhibitors, or S.S.R.I.'s, could raise the risk of suicidal thinking in a small number of children and adolescents. The F.D.A. is scrutinizing suicide attempts by adults reported in drug trials.

The risk is extremely difficult to determine, experts say, in part because suicide attempts are rare.

In one of the new analyses, researchers at the University of Ottawa re-evaluated data from 345 antidepressant trials for depression and other conditions, involving 36,455 men and women. The investigators found 143 total suicide attempts, and found that the rate was twice as high in people who were taking S.S.R.I.'s as it was in those getting placebo pills, or some other form of therapy.

"Many people are on these drugs, which makes the rare risk very important," said Dr. Dean Fergusson of the University of Ottawa, who is a lead author of the study.

Dr. David A. Freedman, a clinical trials expert and statistician at the University of California, Berkeley, who was not involved in any of the studies, said that reviews of this kind are not a very reliable way to determine risks. Moreover, he said, the Ottawa study presumed that all antidepressants affected everyone the same way in terms of suicide risk.

"This is like saying your reaction to Prozac is the same as mine to Zoloft, which we know isn't true," he said. "This assumption exaggerates the significance of their findings."

Dr. Fergusson disagreed, saying the assumption of uniform effect gave a conservative estimate.

In another analysis, also in the British journal, doctors evaluated data from 477 trials involving 40,826 people, which were submitted by drug companies to British regulators for safety review. "We found no evidence that S.S.R.I.'s increased the risk of suicide," and weak evidence that the drugs increased the risk of self harm, the authors concluded.

The third study analyzed case records of 146,095 people prescribed antidepressants for the first time from 1995 to 2001. The researchers found no evidence of increased suicide risk in adults taking S.S.R.I.'s compared with people of the same age and similar histories taking other types of antidepressants.

Given that studies report suicidal behavior in a number of ways, experts are skeptical that reviews of trial data will resolve the issue. "We have machinery to pull diamonds from the earth, but we don't have machinery to pull truth from data in these studies," Dr. Freedman said.

Psychiatrists said the studies were not likely to change how they treat patients: the drugs tend to increase agitation and unusual behavior in the first few weeks after the treatment is started, when patients need to be closely monitored, they said.

Source: http://www.nytimes.com/2005/02/18/n...&en=b0d7480b16a6a11c&ei=5089&partner=rssyahoo (registration required)
Another source: http://www.heraldtribune.com/apps/pbcs.dll/article?AID=/20050218/ZNYT02/502180741
 
Suicide, depression, and antidepressants (scientific babbles)

Patients and clinicians need to balance benefits and harms


Unipolar depression, one of the most important causes of disability worldwide,1 is characterised by depressed mood, hopelessness, helplessness, intense feelings of guilt, sadness, low self esteem, thoughts of self harm, and suicide. Up to 15% of patients with unipolar depression eventually commit suicide.2 Although clinical guidelines recommend treating moderate to severe depression with antidepressant drugs,3 debate persists on whether some antidepressant drugs, in particular the selective serotonin reuptake inhibitors (SSRIs), cause the emergence or worsening of suicidal ideas in vulnerable patients. New insights on this key issue have been provided by three articles published in this issue.

Fergusson et al conducted a systematic review of published randomised controlled trials comparing SSRIs with either placebo or other active treatments in patients with depression and other clinical conditions.4 They found an almost twofold increase in the odds of fatal and non-fatal suicidal attempts in users of SSRIs compared with users of placebo or other therapeutic interventions (excluding tricyclics). No increase in risk was seen, however, when only fatal suicidal attempts were compared between SSRIs and placebo. Finally, no differences were observed when overall suicide attempts were compared between users of SSRIs and tricyclic andidepressants.

By contrast, Gunnell et al included in their review both published and unpublished randomised controlled trials submitted by pharmaceutical companies to the safety review of the Medicine and Healthcare products Regulatory Agency.5 These trials compared SSRIs with placebo in adults with depression and other clinical conditions. Three outcome measures were studied: completed suicide, non-fatal self harm, and suicidal thoughts. The researchers found no evidence for an increased risk of completed suicide, only weak evidence of an increased risk of self harm, and inconclusive evidence of an increased risk of suicidal thoughts (estimates compatible with a modest protective or adverse effect).

Finally, the nested case-control study reported by Martinez et al, based on information extracted from the General Practice Research Database, analysed the risk of non-fatal self harm and suicide in patients with a new diagnosis of depression who were prescribed SSRIs or tricyclics.6 The cohort included 146 095 patients. In comparison with users of tricyclics, users of SSRIs were not at increased risk of suicide or non-fatal self harm. However, in patients aged 18 or less, weak evidence indicated a higher risk of non-fatal self harm in those prescribed SSRIs.

From a methodological viewpoint, these articles highlight the relevance of combining randomised with observational evidence, taking into account the limitations of both approaches. Randomised controlled trials included selected patient populations followed up for short periods of time: these studies were not designed to identify completed or attempted suicides specifically, and reported data on this outcome variable only in a subgroup of studies.4-5 Additionally, given that a diagnosis of unipolar depression was not required for inclusion in the review, trials with different patient populations were included. Although the procedure of pooling data from hundreds of trials increased the overall numbers, absolute numbers of patients attempting and committing suicide remained very low, leaving the possibility that reporting or not reporting a few cases could have completely changed the overall outcome.7 Conversely, the study by Martinez et al analysed a large number of newly depressed patients.6 However, the lack of randomisation raises the problem of confounding by indication because doctors might preferentially prescribe SSRIs on safety grounds in patients at risk of suicide. Although authors adjusted statistically for this potential confounder, the possibility that other known or unknown variables might have acted in unpredictable ways cannot be ruled out.

Taking into account these limitations, we can get some useful insights for clinical practice. Firstly, current evidence that indicates no clear relation between SSRIs and suicide,4-6 8 9 together with available robust evidence of efficacy of treatment with antidepressant drugs in the pharmacological management of moderate to severe unipolar depression, should encourage doctors to prescribe effective doses of these drugs in such patients. Doctors should additionally be aware that SSRIs, similarly to tricyclics, may induce or worsen suicidal ideation and suicide attempts during the early phases of treatment, possibly because they cause agitation and activation particularly at that time. During these early phases, doctors should plan frequent follow up visits and also consider a possible supporting role for family members and caregivers. Patients should be advised against withdrawing treatment abruptly, given the risk of reactions to discontinuation.10 Secondly, the strongest evidence applies to moderate to severe depression only and therefore cannot be extrapolated to mild depression.3 Thirdly, these indications apply to adults only, whereas in children and adolescents the balance between benefits and harms seems to be negative, with little evidence of efficacy and increasing evidence of an association between exposure to SSRIs and other antidepressant drugs and emergence of suicidal thought and behaviours.6-11 This risk, in addition to the lack of data on the long term implications of exposing a developing brain to antidepressant drugs,12 should discourage the routine prescribing of antidepressant drugs in children and adolescents.

Andrea Cipriani, research fellow in psychiatry

Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, 37134 Verona, Italy (andrea.cipriani@medicina.univr.it)

Corrado Barbui, lecturer in psychiatry

Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, 37134 Verona, Italy

John R Geddes, professor of epidemiological psychiatry

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford OX3 7JX

--------------------------------------------------------------------------------
Papers pp 385, 389, 396
Competing interests: JG has received research funding and support from Sanofi-Aventis and GlaxoSmithKline and is currently in discussion with several other companies that manufacture SSRIs about collaboration on planned independent trials and systematic reviews.

References


1) Ustun TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184: 386-92.[Abstract/Free Full Text]
2) Davies S, Naik PC, Lee AS. Depression, suicide, and the national service framework. BMJ 2001;322: 1501-2.[Free Full Text]
3) National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. Clinical Guideline 23. London: NICE, 2004. www.nice.org.uk/pdf/CG023quickrefguide.pdf (accessed 6 Feb 2005).
4) Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005;330: 396-9.[Abstract/Free Full Text]
5) Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330: 385-8.[Abstract/Free Full Text]
6) Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330: 389-93.[Abstract/Free Full Text]
7) Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004;23: 1351-75.[CrossRef][ISI][Medline]
8) Kahn A, Kahn S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003;160: 790-2.[Abstract/Free Full Text]
9) Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292: 338-43.[Abstract/Free Full Text]
10) Medawar C. The antidepressant web—marketing depression and making medicines work. International Journal of Risk & Safety in Medicine 1997;10: 75-126.
11) Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004;363: 1341-5.[CrossRef][ISI][Medline]
12) Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005;365: 451-3.[CrossRef][Medline]
 
I was on procaz and xanna.. it screwed me up back in 1995 I wud have moods swings and etc and cud not pay attention in school so they removed me from school for uh a month and half and I returned part time to mainstream school in dec of 1995 also the meds in my system didn't get out til probably 1997.*yeah it took me a while to get better cuz of meds sure screwed my system.. blah* then finally decided to go deaf school (I made a mistake cuz they weren't nice to me when I first got to deaf school) but lucky I had old friends from mainstream school who went to deaf school before I did. *sighs* I sometimes have nerve pinch cuz of those meds.. :( but now I'm better off meds cuz they make me sick and I wud have hallactions and and all ugh.. but sure I do have depression it's on and off since then.. but I can't say I'm 100% happy with what i do right now ;) so I understand how u people deal with meds cuz u aren't alone either..
 
Back
Top